Eli Lilly, Novo Nordisk face antitrust lawsuit from compounder| STAT
Within the newest fracas over the burgeoning marketplace for weight reduction medication, a compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of utilizing anticompetitive techniques to forestall it from serving sufferers.
Try Specialties claimed the drugmakers entered into unique agreements with telehealth suppliers, which have been then barred from working with compounders; interfered with relationships that compounders have with fee processors and social media platforms; and often disparaged compounded medicines as unlawful or unsafe.
In doing so, Lilly and Novo Nordisk “unlawfully restricted competitors and straight harmed sufferers within the U.S. Consequently, sufferers are compelled to pay inflated costs and endure lowered entry to [the] medicines, significantly customized variations of these medicines,” Try argued in its lawsuit, which was filed in Texas.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
